<DOC>
	<DOC>NCT00139828</DOC>
	<brief_summary>In this postmarketing study, the safety of Nonafact速 (human coagulation factor IX) is evaluated in previous treated and untreated patients with severe, moderate or mild haemophilia B.</brief_summary>
	<brief_title>Post Marketing Study in Haemophilia B Patients Using Nonafact速 (Human Coagulation Factor IX)</brief_title>
	<detailed_description>The clinical efficacy and safety of Nonafact速 has been shown in two pre-authorisation studies. Marketing authorisation for the EU was granted 3 July 2001. The Post Marketing Study, which evaluates the clinical efficacy, immunogenicity and safety of Nonafact速, is set up according to CPMP/BPWG /198/95, rev. 1 (Final, London, 19 October 2000) 'Note for guidance on the clinical investigation of human plasma derived factor VIII and IX products'</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Haemophilia B (mild, moderate or severe), Haemophilia B Leyden or symptomatic carriers of Haemophilia B and Haemophilia B Leyden Above the age of six, at the moment of inclusion Tested positive for HAV and HBV antibodies, induced by infection or vaccination, and negative for HBsAg Informed consent signed by the patients or his legally accepted representative Under the age of six, at the moment of inclusion Tested negative for HAV and HBV antibodies</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>haemophilia B</keyword>
	<keyword>factor IX</keyword>
	<keyword>Product Surveillance, Postmarketing</keyword>
	<keyword>plasma products</keyword>
</DOC>